专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060024352A1 Phytosterol nutritional supplements 有权
公开(公告)号：US20060024352A1
公开(公告)日：2006-02-02
申请号：US11236570
申请日：2005-09-28
申请人： Scott Poxon , William Bubnis , Bruce Sutton , Jeffrey Vernon , Denise Walters , Michael Williams , Neil Wittenberg
发明人： Scott Poxon , William Bubnis , Bruce Sutton , Jeffrey Vernon , Denise Walters , Michael Williams , Neil Wittenberg
IPC分类号： A61K47/00 , A61K31/56
CPC分类号： A61K31/56 , A23L33/11 , A23L33/15 , A23L33/16 , A23V2002/00 , A61K9/0056 , A61K9/009 , A61K9/10 , A61K9/1611 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/4866 , A61K31/355 , A61K31/375 , A61K31/51 , A61K31/525 , A61K31/714 , A61K45/06 , A61K47/02 , A61K2300/00 , A23V2250/1592 , A23V2250/1598 , A23V2250/161 , A23V2250/1642 , A23V2250/1626 , A23V2250/1588 , A23V2250/1612 , A23V2250/1578 , A23V2250/1618 , A23V2250/1608 , A23V2250/1572 , A23V2250/1628 , A23V2250/163 , A23V2250/1636 , A23V2250/702 , A23V2250/7044 , A23V2250/708 , A23V2250/7052 , A23V2250/706 , A23V2250/7056 , A23V2250/712 , A23V2250/2136 , A23V2250/213 , A23V2200/3262 , A23V2250/71 , A23V2250/714 , A23V2250/304 , A23V2250/7046 , A23V2250/72 , A23V2250/705
摘要： The invention provides a nutritional supplement which includes phytosterol to facilitate reduction of cholesterol. The nutritional supplement may be a swallowable tablet, chewable tablet, sachet, capsule or suspension. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized swallowable tablet and a method for reducing blood cholesterol in humans.

2. 发明申请

US20050214383A1 Multi-vitamin and mineral nutritional supplements 审中-公开
标题翻译：多种维生素和矿物质营养补品
公开(公告)号：US20050214383A1
公开(公告)日：2005-09-29
申请号：US11090486
申请日：2005-03-28
申请人： William Bubnis , Richard Cotter , Paul Herman , Judith Moreines , Scott Poxon , Bruce Sutton , Jeffrey Vernon , Denise Walters , Michael Williams , Neil Wittenberg
发明人： William Bubnis , Richard Cotter , Paul Herman , Judith Moreines , Scott Poxon , Bruce Sutton , Jeffrey Vernon , Denise Walters , Michael Williams , Neil Wittenberg
IPC分类号： A61K31/51 , A61K31/525 , A61K31/56 , A61K31/714
摘要： The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.
摘要翻译：本发明提供一种营养补充剂，其包括促进人体胆固醇降低和/或降低半胱氨酸和/或降低低密度脂蛋白胆固醇（LDL-C）氧化的微量营养素。在一个实施方案中，补充剂是多种维生素，矿物质补充剂，其包括已知降低胆固醇的至少一种组分。本发明还提供了将实用大小的片剂中含有植物甾醇的营养补充剂的每日有效剂量的四分之一到一半的压片和降低人体血液胆固醇的方法。

3. 发明申请

US20090285796A1 MUTANT JAK3 KINASE IN HUMAN LEUKEMIA 审中-公开
标题翻译： MUTANT JAK3激活人类LEUKEMIA
公开(公告)号：US20090285796A1
公开(公告)日：2009-11-19
申请号：US12161512
申请日：2007-01-19
申请人： Valerie Goss , Ting-lei Gu , Roberto Polakiewicz , Brian Druker , Denise Walters
发明人： Valerie Goss , Ting-lei Gu , Roberto Polakiewicz , Brian Druker , Denise Walters
IPC分类号： A61K39/395 , C07H21/04 , C07K14/00 , C12N15/63 , C12N5/10 , C12N9/12 , C07K16/00 , C12Q1/68 , G01N33/53 , A61K31/7088 , A61P35/02
CPC分类号： C12N9/1205 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： In accordance with the invention, a novel activating mutation (alanine 572 to valine) in JAK3 kinase has been discovered in human acute myelogenous leukemia (AML). The mutant JAK3 kinase was confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant JAK3 kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the mutant polypeptides. The disclosed identification of this new mutant protein and enables new methods for determining the presence of mutant JAK3 kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the mutant proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
摘要翻译：根据本发明，已经在人类急性骨髓性白血病（AML）中发现JAK3激酶中的新的活化突变（丙氨酸572至缬氨酸）。证实突变型JAK3激酶能够驱动急性巨核细胞白血病（AML-M7）的增殖和存活。因此，本发明部分地提供分离的多核苷酸和编码所公开的突变体JAK3激酶多肽的载体，用于检测其的探针，分离的突变多肽，重组多肽和用于检测突变体多肽的试剂。所公开的这种新的突变蛋白的鉴定并且使得能够确定生物样品中突变体JAK3激酶多肽的存在的新方法，用于筛选抑制突变蛋白质的化合物的方法，以及用于抑制突变体特征的癌症进展的方法多核苷酸或多肽，其也由本发明提供。

4. 发明申请

US20090197269A1 Translocation and mutant CSF1R Kinase in human leukemia 审中-公开
标题翻译：人类白血病易位和突变型CSF1R激酶
公开(公告)号：US20090197269A1
公开(公告)日：2009-08-06
申请号：US12214616
申请日：2008-06-20
申请人： Ting-Lei Gu , Valerie Goss , Robert Polakiewicz , Brian Druker , Denise Walters
发明人： Ting-Lei Gu , Valerie Goss , Robert Polakiewicz , Brian Druker , Denise Walters
IPC分类号： C12Q1/68 , C12N15/11 , C12N15/00 , C12N15/87 , C12N5/06 , C12P21/00 , C12N9/96 , C07K16/18 , G01N33/574 , C12Q1/48
CPC分类号： C12Q1/6886 , C07K14/47 , C07K14/7153 , C07K2319/00 , C12N9/1205 , C12Q2600/106 , C12Q2600/136 , G01N2500/04
摘要： In accordance with the invention, a novel gene translocation, (3p21, 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1R) kinase has now been identified. The RBM6-CSF1R fusion protein and truncated CSF1R kinase itself, which both retain CSF1R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant CSF1R kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
摘要翻译：根据本发明，在人骨髓性白血病（AML）中的新型基因易位（3p21,5q33），其导致将部分RNA结合蛋白-6（RBM6）与巨噬细胞集落刺激因子-1受体（RBF6）结合的融合蛋白 CSF1R）激酶已被鉴定。确认RBM6-CSF1R融合蛋白和截短的CSF1R激酶本身都保留了CSF1R酪氨酸激酶活性，以驱动急性巨核细胞白血病（AML-M7）的增殖和存活。因此，本发明部分地提供分离的多核苷酸和编码所公开的突变型CSF1R激酶多肽的载体，用于检测其的探针，分离的突变多肽，重组多肽和用于检测融合和截短的多肽的试剂。所公开的这种新的融合蛋白和截短的激酶的鉴定使得能够确定生物样品中这些突变型CSF1R激酶多肽的存在的新方法，用于筛选抑制蛋白质的化合物的方法，以及用于抑制癌症进展的方法突变体多核苷酸或多肽，其也由本发明提供。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式